Stem Cell Heart Injections During Laser Revascularization Surgery for Treatment of Chronic Ischemic Heart Disease

Michael Sekela8 enrolled

Overview

Assess the safety and effectiveness of stem cell application with regard to improvement in regional myocardial function in patients receiving Trans-Myocardial Laser Revascularization (TMR) and stem cells.

Multiple case experiences and studies have been published reviewing clinical experiences with Carbon Dioxide Trans-Myocardial Laser Revascularization (TMR) and autologous bone marrow derived cell application. These experiences have demonstrated perfusion improvements, ejection fraction improvements and improvements in angina or heart failure symptoms. The investigators elected to examine the use of CD133 positive (CD133+) BM-derived stem cells because of their pluripotent nature and the fact that during the CD133 selection process inflammatory cells present in the bone marrow are being discarded. CD133+ is a recently discovered marker for more primitive bone marrow derived multipotent stem and endothelial progenitor cells and is of particular interest in studies directed to therapeutic angiogenesis, as these cells have been shown to differentiate into endothelial and myogenic cell lines. Multiple studies have utilized BM derived cells for myocardial regeneration. Patients who received CD133+ cells showed improved perfusion at injection sites of stem cells leading to a significant increase in volume of left ventricular ejection fraction, regional wall motion in the infarct zone, and a reduction in end systolic left ventricular volume.

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Chronic Ischemic Heart Disease

Interventions

Bone Marrow Derived Autologous CD133+ Selected Cell ProductDRUG

Injection of bone marrow derived autologous CD133+ cell product into laser channels during Trans-Myocardial Revascularization

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Presence of at least two vessel coronary artery disease not amenable to direct revascularization * Area of interest defined as part of free left ventricular vall with reduced contractility * Demonstration of reduced perfusion in the area of interest (\>30% of free wall) * Global ejection fraction 30-45% with symptoms class \>\_ II on the NYHA scale * Significant refractory angina defined as symptoms class \>\_ III that are refractory to maximal medical and anti-angina therapy * Expected survival of at least two years Exclusion Criteria: * Any condition that prevents successful stem cell collection or application, e.g. systemic infection, puncture for stem cell collection impossible * Any condition that may adversely affect bone marrow such as malignancy or prior irradiation to the pelvic bone * Mitral valve insufficiency \> moderate grade * History of ventricular arrhythmias not controlled by medication and/or AICD * Need for additional heart surgery (i.e. valve replacement) * Emergency or salvage operation defined as within 48 hours of diagnosis * Evidence of left ventricular thrombus * Previous heart surgery within the last 6 months * Increased Troponin T (\> 3X ULN) in patients with unstable angina at time of intervention * History of symptomatic carotid disease within the last 3 months prior to study intervention * Ejection fraction \< 30% * End stage renal disease * Untreatable cancer, current or within preceding 5 years * Severe COPD

Locations (1)

University of Kentucky Healthcare

Lexington, Kentucky, United States

Outcomes

Primary Outcomes

Occurrence of Treatment-emergent serious adverse events (SAE) and adverse events

Major adverse cardiac event and adverse events defined in the common toxicity criteria

Time frame: Assess from Procedure through 12 months

Secondary Outcomes

Change in left ventricular ejection fraction compared to baseline

Measured as a percentage by Echocardiography

Time frame: Assessed at baseline, 6 months, and 12 months

Change in myocardial regional function compared to baseline

Measured by nuclear scanning.

Time frame: Assessed at baseline and 6 months

Change in myocardial regional viability compared to baseline

Measured by nuclear scanning.

Time frame: Assessed at baseline and 6 months

Change in distance walked compared to baseline

Measured in feet during a 6 minute walk test

Time frame: Assessed at baseline, 3 months, 6 months, and 12 months

Change in quality of life associated with heart failure compared to baseline

Measured using the Kansas City Cardiomyopathy Questionnaire.

Time frame: Assessed at baseline, 3 months, 6 months, and 12 months

Change in class of angina compared to baseline

Measured using the Canadian Cardiovascular Society Grading Scale.

Time frame: Assessed at baseline, 3 months, 6 months, and 12 months.

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.